Trial Profile
International, Multi-center, Open Label, Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Baclofen/naltrexone/sorbitol (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions; Registrational
- Acronyms PLEO-CMT-FU
- Sponsors Pharnext
- 13 Mar 2024 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 06 Jan 2024 This trial has been completed in the Netherlands.
- 24 Dec 2023 This trial has been completed in Belgium according to European Clinical Trials Database record.